| 1 |
NCT03340324 |
Enrolling by invitation |
Open Label Immunotherapy of Endometriosis |
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effect on pelvic pain by visual analogue scale (VAS)
- Effect of V-Endo on complete blood count (CBC)
- Changes induced By V-Endo on life quality
- Effect of V-Endo liver and kidney biochemistry parameters
|
30 |
Female |
18 Years to 50 Years (Adult) |
NCT03340324 |
V-Endo |
|
October 1, 2017 |
June 1, 2018 |
September 1, 2018 |
November 13, 2017 |
November 13, 2017 |
|
- Immunitor LLC
Ulaanbaatar, Mongolia
|
| 2 |
NCT03042741 |
Recruiting |
Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity |
|
- Biological: atherosclerosis vaccine
- Biological: Placebo pills
|
Interventional |
Phase 3 |
- Immunitor LLC
- Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Immunotherapy of atherosclerosis
- Effect on anthropomorphic indices of obesity
- Effect on hypertension
- Effect on glucose levels
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT03042741 |
V6 |
V6 |
February 1, 2017 |
February 18, 2018 |
May 18, 2018 |
February 3, 2017 |
March 28, 2017 |
|
- Immunitor LLC
Ulaanbaatar, CA, Mongolia
|
| 3 |
NCT02395081 |
Completed |
Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia |
- Pregnancy
- Vitamin D Deficiency
|
- Dietary Supplement: 600 IU Vitamin D3 in prenatal vitamin
- Dietary Supplement: 2000 IU Vitamin D3 in prenatal vitamin
- Dietary Supplement: 4000 IU Vitamin D3 in prenatal vitamin
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- National Center for Maternal and Child Health Research, Mongolia
- Zuun Kharaa Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Circulating 25(OH)D serum levels as measured by DiaSorin assay
- Preeclampsia prevalence as measured by new onset hypertension after 20 weeks gestation and proteinuria
- Average monthly change in blood pressure as measured by automated Omron blood pressure cuff
- (and 10 more...)
|
360 |
Female |
18 Years and older (Adult, Senior) |
NCT02395081 |
14-0591-02 |
|
February 2015 |
December 2016 |
December 2016 |
March 20, 2015 |
January 19, 2017 |
|
- Zuun Kharaa Hospital
Zuun Kharaa, Selenge Aimag, Mongolia
|
| 4 |
NCT02276755 |
Active, not recruiting |
Vitamin D Suplementation in TB Prevention |
|
- Dietary Supplement: cholecalciferol (vitamin D)
- Other: Placebo
|
Interventional |
Phase 3 |
- Harvard School of Public Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The primary outcome is acquisition of latent tuberculosis (LTBI) as evidenced by conversion of the QuantiFERON-TB Gold in-tube assay test result from negative to positive.
|
8020 |
All |
6 Years to 13 Years (Child) |
NCT02276755 |
140513 |
|
September 2015 |
June 2019 |
June 2020 |
October 28, 2014 |
February 24, 2017 |
|
- Mongolian Health Initiative
Ulaanbaatar, Mongolia
|
| 5 |
NCT02256514 |
Enrolling by invitation |
Open Label Trial of Immunotherapy for Advanced Liver Cancer |
|
- Biological: Daily oral dose of hepcortespenlisimut-L
|
Interventional |
Phase 2 |
- Immunitor LLC
- Immunitor Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effect of hepcortespenlisimut-L (V5) immunotherapy on serum levels of AFP (IU/ml) compared to baseline
- Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance
- Effect of hepcortespenlisimut-L (V5) immunotherapy in patients with advanced HCC on blood biochemistry parameters
- Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02256514 |
IMMV5 |
HCC |
September 2014 |
September 2019 |
December 2019 |
October 3, 2014 |
April 11, 2017 |
|
- Immunitor LLC
Ulaanbaatar, Mongolia
|
| 6 |
NCT01861431 |
Completed |
Evaluating a Microfinance Intervention for High Risk Women in Mongolia |
|
- Behavioral: HIV Sexual Risk reduction
- Behavioral: HIV Sexual Risk reduction plus Microfinance
|
Interventional |
Not Applicable |
- Columbia University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- unprotected acts of vaginal and anal intercourse;
- proportion of protected vaginal and/or anal acts using barrier protection;
- number of sexual partners
- Proportion of income from sex work
|
107 |
Female |
18 Years and older (Adult, Senior) |
NCT01861431 |
AAAF4402
R34MH093227 |
|
April 2010 |
August 2013 |
December 2013 |
May 23, 2013 |
March 18, 2015 |
|
- Aira Toivgoo, co-PI
Ulaanbaatar,, Mongolia
|
| 7 |
NCT01741051 |
Completed |
A Randomized Air Filter Intervention Study of Air Pollution and Fetal Growth in a Highly Polluted Community |
|
|
Interventional |
Not Applicable |
- Simon Fraser University
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Gestational-age adjusted birthweight
- Birthweight
- Gestational age
- (and 6 more...)
|
540 |
Female |
18 Years and older (Adult, Senior) |
NCT01741051 |
275997 |
|
January 2014 |
December 2015 |
December 2015 |
December 4, 2012 |
December 5, 2016 |
|
- Mongolia National University of Medical Sciences
Ulaanbaatar, Mongolia
|
| 8 |
NCT01657656 |
Completed |
Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia |
- Vitamin D Supplements
- Tuberculosis
- Sputum
- (and 2 more...)
|
- Dietary Supplement: Vitamin D
|
Interventional |
Not Applicable |
- Harvard School of Public Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The primary endpoint will be time to sputum culture conversion from positive to negative.
|
350 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01657656 |
R00HL089710 |
|
October 2012 |
May 2014 |
July 2014 |
August 6, 2012 |
July 30, 2014 |
|
- National Center for Communicable Dieases
Ulaanbaatar, Mongolia
|
| 9 |
NCT00879424 |
Completed |
Vitamin D Supplementation in Childhood Atopic Dermatitis |
|
- Dietary Supplement: cholecalciferol (vitamin D)
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- EASI score
- Investigator Global Assessment (IGA)
|
107 |
All |
2 Years to 17 Years (Child) |
NCT00879424 |
CeDAR-01 |
|
February 2009 |
April 2009 |
May 2009 |
April 10, 2009 |
December 22, 2016 |
|
- National Dermatology Center
Ulaan Baatar, Mongolia
|
| 10 |
NCT00860886 |
Completed |
Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
433 |
Female |
25 Years to 44 Years (Adult) |
NCT00860886 |
999909078
09-C-N078 |
|
March 2, 2009 |
|
|
March 12, 2009 |
April 5, 2018 |
|
- Health Sciences University of Mongolia
Ulaanbaatar, Mongolia
|
| 11 |
NCT03165591 |
Recruiting |
Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer |
- Pancreatic Cancer Non-resectable
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effect of V3-P on tumor burden
- Safety of V3-P
- Effect of V3-P on sugar and bilirubin levels
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03165591 |
Panc-001 |
V3-P |
May 1, 2017 |
February 28, 2020 |
December 31, 2020 |
May 24, 2017 |
May 24, 2017 |
|
- Immunitor LLC
Ulaanbaatar, Mongolia - National Cancer Center
Ulaanbaatar, Mongolia
|
| 12 |
NCT03042182 |
Recruiting |
Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma |
|
- Biological: Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in CA19.9 tumor marker induced by daily dose of oral vaccine V3-X of cholangiocarcinoma
- safety of vaccine
|
20 |
All |
Child, Adult, Senior |
NCT03042182 |
03 |
cholangio |
February 20, 2017 |
February 20, 2019 |
April 20, 2019 |
February 3, 2017 |
April 11, 2017 |
|
- Immunitor LLC
Ulaanbaatar, CA, Mongolia - National Cancer Center
Ulaanbaatar, Mongolia
|
| 13 |
NCT02232490 |
Recruiting |
Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L |
- Hepatocellular Carcinoma
- HCC
- Liver Cancer
|
- Biological: hepcortespenlisimut-L
- Biological: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- changes in plasma AFP
- CT scan
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02232490 |
Immunitor Hepko-V5
IMM05 |
Hepko-V5 |
January 2015 |
November 2018 |
December 2018 |
September 5, 2014 |
April 11, 2017 |
|
- Immunitor LLC
Ulaanbaatar, Mongolia - Immunitor LLC
Ulaanbaatar, Mongolia
|
| 14 |
NCT01061593 |
Completed |
Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV |
|
- Dietary Supplement: Immunoxel
- Other: Placebo
|
Interventional |
Phase 3 |
- Lisichansk Regional Tuberculosis Dispensary
- Ekomed LLC
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To compare the efficacy of combination of Immunoxel with anti-TB treatment versus anti-TB treatment with placebo in adults with sputum smear positive pulmonary tuberculosis
- To confirm the safety of Immunoxel as demonstrated by Liver functions tests (ALT and bilirubin) and hemoglobin; effect on TB-associated wasting by measuring body weight. Effect on lymphocytes and CD4+ cells, CD4/CD8 ratio among those who have HIV.
|
269 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01061593 |
LRTBD-2259 |
|
January 2010 |
March 2015 |
April 2015 |
February 3, 2010 |
May 20, 2015 |
|
- Misheel Lung surgery hospital,
Ulaanbaatar, Ulaanbaatar region, Mongolia - Kharkiv Medical National University
Kharkiv, Ukraine
|
| 15 |
NCT01160549 |
Completed |
Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian Women |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
412 |
Female |
18 Years to 50 Years (Adult) |
NCT01160549 |
999910152
10-C-N152 |
|
August 1, 2010 |
|
|
July 12, 2010 |
April 5, 2018 |
|
- National University of Mongolia, School of Social Science
Baga Toirog, Mongolia - Bulgan General Hospital
Ulaanbaatar, Mongolia - Maternal and Child Health Research Center (MCHRC)
Ulaanbaatar, Mongolia - Selenge General Hospital
Ulaanbaatar, Mongolia
|
| 16 |
NCT02409290 |
Recruiting |
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB |
|
- Drug: Regimen A locally-used WHO-approved MDR-TB regimen
- Drug: Moxifloxacin
- Drug: Clofazimine
- (and 7 more...)
|
Interventional |
Phase 3 |
- IUATLD, Inc
- Medical Research Council
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- STREAM Stage 2 Primary Outcome Measure (the proportion of patients with a favourable outcome at Week 76)
|
1155 |
All |
18 Years and older (Adult, Senior) |
NCT02409290 |
78372190/18148631 (Stage 1/2) |
STREAM |
April 2016 |
April 2021 |
December 2021 |
April 6, 2015 |
January 26, 2018 |
|
- Beijing Chest Hospital
Beijing, China - Wuhan Institute for TB control
Wuhan, China - Armauer Hanssen Research Institute
Addis Ababa, Ethiopia - (and 15 more...)
|
| 17 |
NCT01973829 |
Recruiting |
The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN) |
- Critical Illness
- Sepsis
- Respiratory Failure
- (and 4 more...)
|
- Other: Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Adherence to best critical care practices
- ICU and hospital lengths of stay
- Mortality for 4 weeks
|
15000 |
All |
18 Years and older (Adult, Senior) |
NCT01973829 |
12-007998 |
|
November 2013 |
March 2018 |
March 2018 |
November 1, 2013 |
January 9, 2018 |
|
- Gomel Regional Clinical Hospital
Gomel, Belarus - University Hospital Banja Luka
Banja Luka, Bosnia and Herzegovina - Sveučilišna klinička bolnica
Mostar, Bosnia and Herzegovina - (and 27 more...)
|
| 18 |
NCT01135056 |
Active, not recruiting |
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) |
|
- Device: SIR-Spheres
- Drug: Sorafenib tosylate
|
Interventional |
Phase 3 |
- Singapore General Hospital
- National Cancer Centre, Singapore
- National Medical Research Council (NMRC), Singapore
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Progression free survival in the liver
- Progression free survival overall
- (and 7 more...)
|
360 |
All |
18 Years and older (Adult, Senior) |
NCT01135056 |
AHCC06 |
SIRveNIB |
July 2010 |
December 2017 |
December 2017 |
June 2, 2010 |
October 5, 2017 |
|
- The Brunei Cancer Centre
Jerudong, Brunei, Brunei Darussalam - Queen Mary Hospital
Hong Kong, Hong Kong, China - University of Udayana, Rumah Sakit Sanglah, Indonesia
Denpasar, Bali, Indonesia - (and 26 more...)
|
Create an RSS feed from your search for:
Download the search results for: